RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-5529
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1117100; Gene model (P.falciparum): PF3D7_0617900; Gene product: histone H3 variant (H3.3)
Transgene
Transgene not Plasmodium: RFP
Promoter: Gene model: PBANKA_1319500; Gene model (P.falciparum): PF3D7_1455800; Gene product: LCCL domain-containing protein (LAP4; LCCL/lectin adhesive-like protein 4; CCp2)
3'UTR: Gene model: PBANKA_1359600; Gene product: transmission blocking target antigen precursor 6-cysteine protein (P48/45)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Transgene
Transgene not Plasmodium: GFP (gfp-mut3)
Promoter: Gene model: PBANKA_0416100; Gene model (P.falciparum): PF3D7_0905300; Gene product: dynein heavy chain, putative
3'UTR: Gene model: PBANKA_1010600; Gene product: calmodulin, putative (cam)
Replacement locus: Gene model: PY17X_0306600; Gene product: 6-cysteine protein (P230p; 230p)
Phenotype Asexual bloodstage; Gametocyte/Gamete; Fertilization and ookinete; Oocyst; Sporozoite;
Last modified: 11 July 2024, 23:16
  *RMgm-5529
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 38199522
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 820cl1m1cl1 (RMgm-164)
Other information parent lineP. berghei ANKA 820cl1m1cl1 (RMgm-164) is a reference ANKA mutant line which expresses GFP under control of a male and RFP under control of a female gametocyte specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 19438517).
The mutant parasite was generated by
Name PI/ResearcherTateishi YS, Annoura T
Name Group/DepartmentDepartment of Parasitology
Name InstituteNational Institute of Infectious Diseases
CityShinjuku-ku, Tokyo
CountryJapan
Name of the mutant parasite
RMgm numberRMgm-5529
Principal nameΔh3.3_b
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageReduced growth/multiplication rate of asexual blood stages.
Gametocyte/GameteMale gamete production (exflagellation) comparable to wild type.
Fertilization and ookineteMale gamete production (exflagellation) comparable to wild type. Fertilized zygotes exhibited an early-stage growth arrest with strongly reduced mature ookinetes (mainly round, retort and degenerated zygotes).
OocystReduced numbers of oocysts with smaller size compared to wild type.
SporozoiteNo sporozoites in salivary glands.
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of histone H3.3 and expresses GFP under control of a male and RFP under control of a female gametocyte specific promoter.

Protein (function)
Two conserved histone H3 proteins (canonical H3 and variant H3.3; PBANKA_0108800 and PBANKA_1117100) were identified as gene annotations in the Plasmodium genomic database (http://www.plasmodb.org). Both histone H3 proteins consist of 136 amino acids with highly conserved sequence homology. The amino acid sequence alignment indicated only eight amino acid differences between these proteins. In addition, the secondary structure prediction revealed four conserved α-helices in both histone H3 proteins. Moreover, the predicted models, built against canonical H3 and H3.3, indicated a high degree of structural similarity between these proteins. The three-dimensional structural prediction based on AlphaFold2 revealed a highly conserved structure between the two histone H3 proteins.
H3.3, a histone H3 variant, is highly conserved in all eukaryotes from yeast to humans, but its function varies among species. H3.3 is deposited into transcribed genes, promoters, and enhancer regions, and it is considered as a mark of transcriptionally active genes in flies, plants, mice and human.However, H3.3 is also incorporated into heterochromatin structures at telomeres, thereby contributing to the maintenance of genomic integrity. In mammals, H3.3 plays an essential role in embryonic development. H3.3 is required for the establishment of heterochromatin in the mouse embryo, and it contributes to chromosome segregation and the maintenance of genome integrity during embryonic development. H3.3 depletion leads to the dysfunction of heterochromatin structures and chromosome distribution, resulting in developmental arrest.
Histone post-translational modifications regulate transcriptional activation in asexual blood stage malaria parasites, consequently controlling the repression of multiple virulence genes and determining sexual stage commitment. Histone H3 modifications are associated with the expression of the var gene family of virulence factors. Histone H3 lysine 9 (H3K9) trimethylation in the 5′ flanking region of var gene contributes epigenetically to repress var gene expression. The replacement of H3K9 acetylation is a key step toward unlocking the silenced var genes. In the genus Plasmodium, H3.3 is highly conserved, and it has diverse localization patterns including both conserved and parasite-specific features. It has been reported that canonical H3 is 'likely essential' for asexual blood stage growth/multiplication, but H3.3 is not essential for asexual blood stage growth/multiplication in malaria parasites. And also it has been reported that Plasmodium H3.3 specifically marks the promoter region of the virulence gene families in its active and poised state, but not the inactive state, and it could contribute to the antigenic variation process, which is critical for pathogenicity.

Phenotype
See also RMgm-5528 for a mutant (Δh3.3_a) lacking expression of H3.3 (that expresses GFP under control of the constitutive eef1a promoter). Another h3.3 gene deletion mutant (Δh3.3_b) was generated (RMgm-5529) using the P. berghei reporter line 820cl1m1cl1, in which male gametocytes express GFP and female gametocytes express RFP.

Reduced growth/multiplication rate of asexual blood stages. Male gamete production (exflagellation) comparable to wild type.
Fertilized zygotes exhibited an early-stage growth arrest with strongly reduced mature ookinetes (mainly round, retort and degenerated zygotes).
Reduced numbers of oocysts with smaller size compared to wild type. No sporozoites in salivary glands.

Additional information
Another h3.3 gene deletion mutant (Δh3.3_b) was generated (RMgm-5529) using the P. berghei reporter line 820cl1m1cl1, in which male gametocytes express GFP and female gametocytes express RFP. This parasite line allowed to perform male and female gametocyte selection/purification and detailed analysis. Δh3.3_b strain exhibited similar phenotypes as Δh3.3_a. This line produced numbers of male and female gametocytes comparable to wild type parasites, indicating that H3.3 is not required for production of female gametocytes. Western blot analysis revealed histone H3 (PBANKA_0108800) protein expression was comparable between the mutant and WT.

To examine the expression of H3.3 in male and female gametocytes, a HA-tagged h3.3-complemented mutant (h3.3::ha (c)_b) was  generated in Δh3.3_b based on the 820cl1m1cl1 line (see RMgm-5530). h3.3::ha (c)_b displayed similar asexual growth rate and production numbers of salivary gland sporozoites as the WT. Male or female gametocytes were sorted into GFP-expressing male gametocytes and RFP-expressing female gametocytes by cytometry. Western blot analysis revealed that the majority of H3.3-HA was detected in female gametocytes.

RNA-seq analysis of purified male and female gametocytes of Δh3.3_b (RMgm-5529) revealed that in both male and female Δh3.3-b gametocytes, the expression of stage-specific genes essential for sexual development was not decreased upon the loss of H3.3, indicating that H3.3 might not play a crucial role in the transcriptional regulation of stage-specific gene expression in male and female gametocytes.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1117100
Gene Model P. falciparum ortholog PF3D7_0617900
Gene producthistone H3 variant
Gene product: Alternative nameH3.3
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationTo generate H3.3-deficient mutants, Pbh3.3 (PBANKA_1117100) was deleted using standard transfection methods with h3.3 gene deletion construct. This construct was created using a modified two-step PCR method. Target sequences for homologous recombination were amplified from WT P. berghei genomic DNA using primers specific for the 5′ or 3′ flanking regions of h3.3. This construct was used to replace the Pbh3.3 endogenous locus with the positive/negative selectable marker (hdhfr::yfcu) cassette by double cross-over homologous recombination, resulting in the generation of PbΔh3.3 mutants (lines PA0184cl3: Δh3.3_a1, PA0185cl1: Δh3.3_a2, and PA0202cl1: Δh3.3_b) after positive selection with pyrimethamine and cloning.

Generation of HA-tagged P. berghei h3.3-complemented mutants
For the complementation of PbΔh3.3 mutants with Pbh3.3, the PbΔh3.3_a2 and PbΔh3.3_b mutants (lines PA0185cl1 and PA0202cl1, respectively) were used. To generate Pbh3.3-complemented parasites, the h3.3::ha tagging construct was used. The target sequences of Pbh3.3 and the Pbh3.3 open-reading frame along with flanking sequences were amplified from WT P. berghei ANKA genomic DNA. This construct was used to reintroduce the HA-tagged h3.3 gene into the h3.3-disrupted locus in Δh3.3_a2 and Δh3.3_b, resulting in the generation of HA-tagged P. berghei h3.3-complemented mutants (lines PA0196cl1: h3.3::ha (c)_a1, PA0197cl1: h3.3::ha (c)_a2, and PA0210cl1: h3.3::ha (c)_b) after negative selection with 5-fluorocytosine and cloning.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameRFP
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedure5-fluorocytosine (5-FC)
Additional remarks genetic modification
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1319500
Gene Model P. falciparum ortholog PF3D7_1455800
Gene productLCCL domain-containing protein
Gene product: Alternative nameLAP4; LCCL/lectin adhesive-like protein 4; CCp2
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_1359600
Gene producttransmission blocking target antigen precursor 6-cysteine protein
Gene product: Alternative nameP48/45
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameGFP (gfp-mut3)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedure5-fluorocytosine (5-FC)
Additional remarks genetic modification
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_0416100
Gene Model P. falciparum ortholog PF3D7_0905300
Gene productdynein heavy chain, putative
Gene product: Alternative name
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_1010600
Gene productcalmodulin, putative
Gene product: Alternative namecam
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PY17X_0306600
Gene product6-cysteine protein
Gene product: Alternative nameP230p; 230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4